Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 4/20 | 0.42 |
| ▸ | HTR2A | P28223 | 3/20 | 0.42 |
| ▸ | HTR2B | P41595 | 3/20 | 0.42 |
| ▸ | CHRNB2 | P17787 | 2/20 | 0.41 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.41 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.39 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.39 |
| ▸ | KDM1A | O60341 | 2/20 | 0.38 |
| ▸ | KDM1B | Q8NB78 | 1/20 | 0.38 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1047199 | 1.00 | HTR2C (0.42) | HTR2CHTR2AHTR2BCHRNB2CHRNA4 | |
| SCHEMBL7376647 | 0.86 | HTR2C (0.42) | HTR2CHTR2AHTR2BCHRNB2CHRNA4 | |
| SCHEMBL10724594 | 0.84 | HTR2A (0.49) | HTR2CHTR2AHTR2BTAAR1SIGMAR1 | |
| SCHEMBL9278829 | 0.83 | HTR2C (0.59) | HTR2CHTR2AHTR2BCHRNB2CHRNA4 | |
| SCHEMBL1897659 | 0.83 | HTR2C (0.59) | HTR2CHTR2AHTR2BCHRNB2CHRNA4 | |
| Hydrochloric Acid SCHEMBL9672275 | 0.81 | HTR2C (0.57) | HTR2CHTR2AHTR2BCHRNB2CHRNA4 | |
| SCHEMBL3886540 | 0.77 | ADRA2A (0.39) | HTR2CHTR2AHTR2BSIGMAR1 | |
| SCHEMBL7109787 | 0.77 | HTR2C (0.45) | HTR2CHTR2AHTR2B | |
| SCHEMBL448237 | 0.77 | CHRNB2 (0.39) | HTR2CHTR2ACHRNB2CHRNA4 | |
| SCHEMBL352937 | 0.77 | SIGMAR1 (0.47) | HTR2CHTR2AHTR2BHRH3KDM1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11319323-B2 | Substituted pyrazolo[4,3-H]quinazolines as protein kinase inhibitors | SHENGKE PHARMACEUTICALS (JIANGSU) LTD. (CN) | 2022-05-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11319323-B2 | Substituted pyrazolo[4,3-H]quinazolines as protein kinase inhibitors | CDK1, CDK2, CDK3 | HTR2C 1782/4885HTR2A 3511/4885HTR2B 3257/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.